Dyne announces new long-term data from DMD clinical trial skipping Exon 51

CureDuchenne provided early funding to Dyne Therapeutics, and is pleased to share that Dyne has released new long-term data from the DELIVER trial in individuals amenable to skipping Exon 51.  At the 6-month time point, individuals treated with 20 mg/kg of DYNE-251 every 4 weeks had a mean absolute dystrophin expression of 8.72% of normal (adjusted for muscle content).  Improvements in functional outcomes were also observed through 18 months, including improvements in Stride Velocity 95^th Centile (SV95C) that exceeded the published proposed minimal clinically important difference (MCID).  Full data from the DELIVER trial is expected in late 2025, and Dyne plans on submitting a Biologics License Application (BLA) to the FDA for accelerated approval in early 2026.

Read the full press release:
https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-long-term-clinical-data-phase-12